The artemisinin derivative artesunate inhibits corneal neovascularization by inducing ROS-dependent apoptosis in vascular endothelial cells

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 5, 2013, Pages 3400-3409

  Cheng, Rui ^a,f   Li, Cen ^a   Li, Chaoyang ^b   Wei, Ling ^a   Li, Lei ^a   Zhang, Yang ^a,c   Yao, Yachao ^a   Gu, Xiaoqiong ^a,d   Cai, Weibin ^a   Yang, Zhonghan ^a   Ma, Jianxing ^f   Yang, Xia ^a,e   Gao, Guoquan ^a,e  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^d GUANGZHOU WOMEN AND CHILDREN S MEDICAL CENTER   (China)

^e SUN YAT SEN UNIVERSITY   (China)

^f UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Apoptosis; Artemisinin; Corneal neovascularization; Free radicals

Indexed keywords

ACETYLCYSTEINE; ARTESUNATE; CASPASE 3; CASPASE 9; CD31 ANTIGEN; CYTOCHROME C; DEFEROXAMINE; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PROTEIN BAX; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; DRUG EFFICACY; EPITHELIUM CELL; FLOW CYTOMETRY; KERATITIS; MITOCHONDRIAL MEMBRANE POTENTIAL; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; SLIT LAMP; VISUAL ACUITY; WESTERN BLOTTING;

APOPTOSIS; ARTEMISININ; CORNEAL NEOVASCULARIZATION; FREE RADICALS;

ANGIOGENESIS INHIBITORS; ANIMALS; ANNEXIN A5; ANTIMALARIALS; APOPTOSIS; ARTEMISININS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; BURNS, CHEMICAL; CORNEAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; EYE BURNS; FEMALE; FLOW CYTOMETRY; IN SITU NICK-END LABELING; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; SODIUM HYDROXIDE;

EID: 84878133739     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.12-11068     Document Type: Article

References (37)

1. Chang JH, Gabison EE, Kato T, Azar DT. Corneal neovascularization. Curr Opin Ophthalmol. 2001;12:242-249.
2. Casey R, Li WW. Factors controlling ocular angiogenesis. Am J Ophthalmol. 1997;124:521-529.
3. Price MO, Thompson RW Jr, Price FW Jr. Risk factors for various causes of failure in initial corneal grafts. Arch Ophthalmol. 2003; 121:1087-1092.
4. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27-31.
5. Folkman J. Angiogenesis. Annu Rev Med. 2006;57:1-18.
6. Klayman DL. Qinghaosu (artemisinin): an antimalarial drug from China. Science. 1985;228:1049-1055.
7. Golenser J, Waknine JH, Krugliak M, Hunt NH, Grau GE. Current perspectives on the mechanism of action of artemisinins. Int J Parasitol. 2006;36:1427-1441.
8. White NJ. Qinghaosu (artemisinin): the price of success. Science. 2008;320:330-334.
9. Efferth T. Molecular pharmacology and pharmacogenomics of artemisinin and its derivatives in cancer cells. Curr Drug Targets. 2006;7:407-421.
10. Berger TG, Dieckmann D, Efferth T, et al. Artesunate in the treatment of metastatic uveal melanoma-first experiences. Oncol Rep. 2005;14:1599-1603.
11. Singh NP, Panwar VK. Case report of a pituitary macroadenoma treated with artemether. Integr Cancer Ther. 2006;5:391-394.
12. Efferth T. Willmar Schwabe Award 2006: antiplasmodial and antitumor activity of artemisinin-from bench to bedside. Planta Med. 2007;73:299-309.
13. Chen HH, Zhou HJ, Wu GD, Lou XE. Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1. Pharmacology. 2004;71:1-9.
14. Laria C, Alio JL, Ruiz-Moreno JM. Combined non-steroidal therapy in experimental corneal injury. Ophthalmic Res. 1997; 29:145-153.
15. Yang H, Cheng R, Liu G, et al. PEDF inhibits growth of retinoblastoma by anti-angiogenic activity. Cancer Sci. 2009;100: 2419-2425.
16. Pan J, Quintas-Cardama A, Kantarjian HM, et al. EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation. Blood. 2007;109:315-322.
17. Firestone GL, Sundar SN. Anticancer activities of artemisinin and its bioactive derivatives. Expert Rev Mol Med. 2009;11:e32.
18. Li C, Li L, Cheng R, et al. Acidic/neutral amino acid residues substitution in NH2 terminal of plasminogen kringle 5 exerts enhanced effects on corneal neovascularization. Cornea. 2013; 32:680-688.
19. McGhee CN, Dean S, Danesh-Meyer H. Locally administered ocular corticosteroids: benefits and risks. Drug Saf. 2002;25:33-55.
20. Chung JH, Kang YG, Kim HJ. Effect of 0.1% dexamethasone on epithelial healing in experimental corneal alkali wounds: morphological changes during the repair process. Graefes Arch Clin Exp Ophthalmol. 1998;236:537-545.
21. Gelatt KN, Mackay EO. The ocular hypertensive effects of topical 0.1% dexamethasone in beagles with inherited glaucoma. J Ocul Pharmacol Ther. 1998;14:57-66.
22. Holland EJ, Bartlett JD, Paterno MR, Usner DW, Comstock TL. Effects of loteprednol/tobramycin versus dexamethasone/tobramycin on intraocular pressure in healthy volunteers. Cornea. 2008;27:50-55.
23. Han Y, Shao Y, Lin Z, et al. Netrin-1 simultaneously suppresses corneal inflammation and neovascularization. Invest Ophthalmol Vis Sci. 2012;53:1285-1295.
24. Batty KT, Le AT, Ilett KF, et al. A pharmacokinetic and pharmacodynamic study of artesunate for vivax malaria. Am J Trop Med Hyg. 1998;59:823-827.
25. Byakika-Kibwika P, Lamorde M, Mayito J, et al. Pharmacokinetics and pharmacodynamics of intravenous artesunate during severe malaria treatment in Ugandan adults. Malar J. 2012;11:132.
26. Hengartner MO. The biochemistry of apoptosis. Nature. 2000; 407:770-776.
27. Disbrow GL, Baege AC, Kierpiec KA, et al. Dihydroartemisinin is cytotoxic to papillomavirus-expressing epithelial cells in vitro and in vivo. Cancer Res. 2005;65:10854-10861.
28. Mercer AE, Maggs JL, Sun XM, et al. Evidence for the involvement of carbon-centered radicals in the induction of apoptotic cell death by artemisinin compounds. J Biol Chem. 2007;282:9372-9382.
29. Handrick R, Ontikatze T, Bauer KD, et al. Dihydroartemisinin induces apoptosis by a Bak-dependent intrinsic pathway. Mol Cancer Ther. 2010;9:2497-2510.
30. Efferth T, Benakis A, Romero MR, et al. Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron. Free Radic Biol Med. 2004;37:998-1009.
31. Sadava D, Phillips T, Lin C, Kane SE. Transferrin overcomes drug resistance to artemisinin in human small-cell lung carcinoma cells. Cancer Lett. 2002;179:151-156.
32. Lai H, Singh NP. Selective cancer cell cytotoxicity from exposure to dihydroartemisinin and holotransferrin. Cancer Lett. 1995;91: 41-46.
33. Lai H, Sasaki T, Singh NP, Messay A. Effects of artemisinin-tagged holotransferrin on cancer cells. Life Sci. 2005;76:1267-1279.
34. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature. 2001;410:37-40.
35. Cowan KJ, Storey KB. Mitogen-activated protein kinases: new signaling pathways functioning in cellular responses to environmental stress. J Exp Biol. 2003;206:1107-1115.
36. Chen YJ, Liu WH, Kao PH, Wang JJ, Chang LS. Involvement of p38 MAPK-and JNK-modulated expression of Bcl-2 and Bax in Naja nigricollis CMS-9-induced apoptosis of human leukemia K562 cells. Toxicon. 2010;55:1306-1316.
37. Lu JJ, Meng LH, Cai YJ, et al. Dihydroartemisinin induces apoptosis in HL-60 leukemia cells dependent of iron and p38 mitogen-activated protein kinase activation but independent of reactive oxygen species. Cancer Biol Ther. 2008;7:1017-1023.